Table 4.
Ongoing clinical trials of perioperative systemic treatment for colorectal liver metastases.
| Trial | Patients | Design | Primary Objective |
|---|---|---|---|
| NCT04003792 | Unresectable | FOLFIRI + Bevacizumab + HAIC (oxaliplatin) | Conversion rate to complete resection |
| NCT02102789 | Unresectable | FOLFOX + HAIC (Floxuridine and Dexamethasone) vs. FOLFOX | Conversion rate to complete resection |
| NCT00482222 | Resectable | FOLFOX for 12 weeks—Surgery -FOLFOX for 12 weeks vs. FOLFOX + Cetuximab for 12 weeks-Surgery -FOLFOX + Cetuximab for 12 weeks |
PFS |
| NCT00492999 | Unresectable | FOLFOX/FOLFIRI +HAIC (Floxuridine and Dexamethasone) |
Conversion rate to complete resection |
| NCT03401294 | Unresectable | FOLFOXIRI + Bevacizumab | Conversion rate to complete resection |
| NCT04552093 | Resectable | FOLFOX/FOLFIRI + HAIC (Floxuridine) -Surgery |
Completion of 2 cycles (feasibility) |
Abbreviations: FOLFIRI: 5-FU/LV and irinotecan; FOLFOX: 5-FU/LV and oxaliplatin; FOLFOXIRI: 5-FU/LV, oxaliplatin and irinotecan; HAIC: Hepatic artery infusional chemotherapy; PFS: Progression-free survival; OS: Overall survival.